Medicine and Dentistry
Chemotherapy
90%
Patient
72%
Troxacitabine
54%
Cytarabine
36%
Combination Therapy
27%
Chemotherapy Regimens
27%
Tezacitabine
27%
Side Effect
18%
Vincristine
18%
Dexamethasone
18%
Methotrexate
18%
Asparaginase
18%
Symptom
18%
Desquamation
18%
Topotecan
18%
Fludarabine
18%
Patient with Leukemia
18%
Inpatient
18%
Adverse Event
9%
Toxicity
9%
Drug Megadose
9%
Steroid
9%
Erythema
9%
Walking Difficulty
9%
Antiinfective Agent
9%
Chemotherapeutic Agent
9%
Pain
9%
Salicylate Sodium
9%
Hand Foot Syndrome
9%
Dimethyl Sulfoxide
9%
Recall
9%
Antimitotic Agent
9%
7 Hydroxystaurosporine
9%
Therapeutic Procedure
9%
Skin
9%
Cancer
9%
Nucleoside Analogue
9%
Pharmacology, Toxicology and Pharmaceutical Science
Troxacitabine
54%
Dolastatin
54%
Cytarabine
36%
Tezacitabine
27%
Side Effect
18%
Methotrexate
18%
Dexamethasone
18%
Vincristine
18%
Asparaginase
18%
Topotecan
18%
Fludarabine
18%
Desquamation
18%
Symptom
18%
Radiation
18%
Toxicity
9%
Adverse Event
9%
Steroids
9%
Nucleoside Analog
9%
Dimethyl Sulfoxide
9%
Pain
9%
Hand Foot Syndrome
9%
Salicylate Sodium
9%
Antimitotic Agent
9%
Erythema
9%
7 Hydroxystaurosporine
9%
Walking Difficulty
9%
Syndrome
9%
Protein Kinase Inhibitor
9%
INIS
patients
100%
chemotherapy
72%
therapy
27%
symptoms
18%
leukemia
18%
doses
18%
side effects
18%
washout
18%
methotrexate
18%
dexamethasone
18%
levels
9%
radiations
9%
proteins
9%
skin
9%
kinases
9%
toxicity
9%
refractories
9%
erythema
9%
malignancies
9%
pain
9%
irradiation
9%
steroids
9%
cytidine
9%
nucleosides
9%
dmso
9%